Orion R&D

Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.

Read more

LEVALS study results assessing the effects of oral levosimendan in patients with ALS published

The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.

Read more

Orion's R&D Pipeline

Research areas

Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs. 

Read more

Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Read more

Drug development

What does it take to develop a new medicine? To start with, you need a dedicated team of top scientists and other professionals. The journey might take up to fifteen years. Take a look!

Read more

Pharmaceutical R&D Ethics Policy

Like in all other operations, our aim is to work in accordance with the requirements, standards and ethical codes of our industry in our pharmaceutical research and development activities too. Our R&D Policy highlights how we make sure that our practices are on an ethically sustainable basis. 

Read more

Partnering and licensing

Partnerships and networking are important for Orion throughout the entire value chain of operations. We collaborate with other companies in research and development, manufacturing and marketing of products internationally.

Read more